London

Filtering by: London

Bridging Frontiers in Space Medicine: Translational science in extreme environments
Feb
7
6:00 PM18:00

Bridging Frontiers in Space Medicine: Translational science in extreme environments

This lecture will encompass innovations in medical research and telecommunications generated through the medium of manned space exploration. The large distances covered in space flight missions and the demands on human physiology with the extreme environment of space have driven the need for methods of effective communication between astronauts and medical teams and the need for ways of mediating effective physiological support. Professor Thais Russomano and Professor Stephen Harridge of King's College London will lead us through an exploration of such topics and provide an insight into the pioneering realm of space medicine.

There will be a networking session & drinks reception after the event!

As always, this event is free and everyone is welcome.

 

View Event →
How A Bad Commercial Strategy Can Kill A Great Technology
Nov
16
6:30 PM18:30

How A Bad Commercial Strategy Can Kill A Great Technology

  • Lecture Theatre 1, London Business School (map)
  • Google Calendar ICS

As a researcher, what does it mean to develop a commercial strategy and if the underlying technology is great (so compelling that it sells itself) do you really need one? We will discuss the ‘sad’ case of a researcher who put his all into commercialising a new technology but who - after burning through his cash had sales that ‘approximated to zero’. We are going to ask whether it was the technology, the market need or his commercial strategy that was to blame. And what he should do next. Along the way we will decompose the elements of a commercial strategy so that you can apply the same framework to yours.

Participants will be emailed some short pre-workshop material to read over 1 week in advance. Please look over this to ensure you are ready to get the most from the workshop.

GUEST SPEAKER: DR JEFF SKINNER

LECTURE THEATRE 1, LONDON BUSINESS SCHOOL, NW1 4SA (6:30 PM TO 9:30 PM)

Jeff Skinner is Director of the Institute of Innovation and Entrepreneurship at London Business School. He actively mentors, encourages and teaches dozens of aspiring entrepreneur MBA students each year. The rest of his time is spent elsewhere in Europe working with scientists who yearn to commercialise their technology and training the technology transfer managers who guide them. Prior to this he was Commercial Director at UCL where he built and ran the spin-out, licensing, R&D collaboration and consultancy units. He holds a PhD from UCL and a MBA from LBS.

View Event →
SIUFocus London: Brexit - The Divorce Battle over Life Sciences and Funding
Jun
8
7:00 PM19:00

SIUFocus London: Brexit - The Divorce Battle over Life Sciences and Funding

  • LGS, Imperial College Business School, South Kensington Campus (map)
  • Google Calendar ICS

On June 23, 2016, the United Kingdom voted to leave the European Union in what could either be described as a catastrophic self-destruction or a glorious grasp at independence. Wrapped up in a state of confusion over their status in the United Kingdom are scientists from Europe and abroad. 

Despite the constant reassurance from academia and industry about scientists’ current status, scientists are worried about what would happen to their jobs and funding after the UK officially leaves the EU in 2019. Will the scientific sector in the UK suffer from less funding from Europe? Will scientists in the EU and abroad flock to other countries such as France or Germany? What type of incentive system should the UK set up in order to continue to attract the greatest minds from around the world?

These are a few of a multitude of questions that will be addressed during this session to understand the direction Brexit will take science in the UK.

GUEST SPEAKERS: BETH THOMPSON, KIMBERLY CORNFIELD, MICHAEL BROWNE

LGS, Imperial College Business School, South Kensington Campus, London, SW7 2AZ

The event will proceed as follows:
19:00-19:20 Beth Thompson, Policy Adviser, Wellcome Trust
19:20-19:40 Kimberly Cornfield, Head of Proposal Management, University College London
19:40-20:00 Michael Browne, Head of European Research & Innovation, University College London
20:00-20:20 Q&A and panel discussion

View Event →
The Power of Big Data: Advancing Healthcare in the Electronic Era
Apr
27
6:30 PM18:30

The Power of Big Data: Advancing Healthcare in the Electronic Era

  • JZ Young Lecture Theatre Anatomy Building (map)
  • Google Calendar ICS

The field of computational biology has seen dramatic growth over the past few years. The significant advances in computing power are now being used to conduct data analytics, mathematical modelling and computational simulation, for an ever-increasingly diverse set of problems. With applications in genomics, neuroscience and medicine, we look to gain an understanding of its future implications with the emergence of Artificial Intelligence and Machine Learning and how this will disrupt and revolutionise both medicine and healthcare.

Program:

- 18:40-19:00 Speaker 1: Victor Dillard, COO, Desktop Genetics

- 19:00-19:20 Speaker 2: Alex Gutteridge, Director, Computational Biology GSK

- 19:20-19:40 Speaker 3: Dr. Parashkev Nachev, Senior Clinical Research, Inst. of Neurology

- 19:40-20:20 Q&A and panel discussion

- 20:20-21:00 Drinks and nibbles. Location: Malet Place, Engineering Building 1.20

 

Alex Gutteridge is a Director in the GSK Computational Biology group with responsibility for coordinating Computational Biology Neuroscience research. Alex has 7 years of experience as a Senior Scientist and Principal Scientist within the pharmaceutical industry. His current research focuses on modelling Human disease for drug discovery using informatics and genomics.

 

Dr. Parashkev Nachev is a Senior Clinical Research Associate at the Institute of Neurology and an honorary Consultant Neurologist at the National Hospital, Queen Square, London. His research deals primarily with translational aspects of cognitive and behavioural neurology, in particular with the development of novel methodology for distributed investigational and therapeutic devices.

 

Victor Dillard is Chief Operating Officer and Cofounder of Desktop Genetics. Desktop Genetics have raised $3.2 million to build A.I. that helps discover and treat the genetic causes of disease, by re-engineering the human genome. The founders sought to use CRISPR genome editing for research and clinical medicine with their London-based startup working at the intersection of tech and biotech.

View Event →
London Session 4: Taking Ownership of Your Big Idea: How to Get a Patent
Mar
23
6:30 PM18:30

London Session 4: Taking Ownership of Your Big Idea: How to Get a Patent

In biotech, like in many sectors, patents are used to increase the potential return of an investment, defend an idea from competitors and bring benefit to a business. In the final session of the Spring 2017 series, our speaker will introduce what an IP is, how to obtain them, and how businesses in the biotech sphere can use them to maximum effect.

GUEST SPEAKER: LUCY WILLIAMS

CHANDLER HOUSE, 2 WAKEFIELD STREET, LONDON WC1N 1PF (6.30PM TO 8PM)

Dr. Lucy Williams, European Patent Attorney, J A Kemp

After obtaining her PhD in developmental biology from University of Cambridge, Lucy decided to become a patent attorney. She chose J A Kemp because of the size and diversity of the firm itself and its Biotechnology and Life Sciences Group.  

As a patent attorney Lucy has a variety of roles. Some of her responsibilities include acting as an intermediary between clients and patent examiners, patent prosecution and drafting new applications and oppositions. 

https://www.linkedin.com/in/lucy-williams-41367133/

View Event →
London Session 3: ACADEMIA AND BIOTECH: THE ENTREPRENEURIAL SCIENTIST
Mar
13
6:00 PM18:00

London Session 3: ACADEMIA AND BIOTECH: THE ENTREPRENEURIAL SCIENTIST

In this talk participants will learn how they can spin out their research into a biotech company without having to leave their academic research behind.

Professor Hans Stauss, Director, Institute of Immunity and Transplantation, UCL.

Professor Hans Stauss was an early trail blazer in the field of cancer immunotherapy demonstrating how modified T cells could be used to effectively target tumours. Recognising the medical potential of this research Hans was involved in setting up Cell Medica which is now advancing an impressive pallet of innovative proprietary technologies in the field of immune cell therapy for cancer and viral infections. Meanwhile Hans continues to turn out cutting edge research and is involved in a number of clinical trials.

View Event →
London Session 4: Turning scientific research into a business
Dec
1
6:00 PM18:00

London Session 4: Turning scientific research into a business

The Science Innovation Union is offering a groundbreaking bio-entrepreneurship course aimed directly at the UK’s top scientists and budding entrepreneurs. The programme consists of a series of four exciting sessions lead by high profile leading academics and industry experts. Head to our website to sign up now! http://science-union.org/siu360-application

Links to other three session in the SIU360 series:
Session 1: https://www.facebook.com/events/1632034013488876/
Session 2: https://www.facebook.com/events/549654898557804/
Session 3: https://www.facebook.com/events/1653754461601574/

Session 4: In the final session of the series we explore the process of creating translational start-ups and technologies. Attendees will discover the life-cycle of a start-up and the hurdles that must be overcome. Additionally, risk-assessment and idea development will be explored.

Speaker: Matthew Durdy
Matthew joined the Cell and Gene Therapy Catapult in 2012, from the novel therapeutics company Aqix, where he was Chief Executive. He has broad experience in the biotechnology industry leading SMEs, raising finance and commercialising diagnostics, medical devices, and therapeutics for regulated use in the EU. He was also an expert advisor to the World Health Organisation on medical innovation strategy. Matthew was also a Director at the venture capital firm CDC, where he was responsible for due diligence and new investment in their $3.5bn international portfolio.

View Event →
London Session 3: Gaining the support of large organisations
Nov
21
6:00 PM18:00

London Session 3: Gaining the support of large organisations

The Science Innovation Union is offering a groundbreaking bio-entrepreneurship course aimed directly at the UK’s top scientists and budding entrepreneurs. The programme consists of a series of four exciting sessions lead by high profile leading academics and industry experts. Head to our website to sign up now! http://science-union.org/siu360-application

Links to other three session in the SIU360 series:
Session 1: https://www.facebook.com/events/1632034013488876/
Session 2: https://www.facebook.com/events/549654898557804/
Session 4: https://www.facebook.com/events/104791129993224/

Session 3: Findings through scientific research can be grand. In an academic environment, these high impact findings may not necessarily reach the public, even though it may directly affect this audience. Collaborating with large organisations, biotech companies, and the government may jump this hurdle. In this session, attendes will learn how to pitch outreach ideas to these organisations, and how to highlight benefits to that organisation in participating in translating scientific research that may not necessarily be a product of their institution. 

Speaker: Tijana Duric. 
GSK is working with many partners to eliminate and control some of the neglected tropical diseases. Tijana has been with GSK for 7 years, enetering as a supply chain manager. Her role now is tailored towards private-public partnerships and global health. Tijana looks after the supply planning for albendazole, a treatment for a variety of parasitic worm infections.

View Event →
London Session 2: Developing strategies for public engagement
Nov
3
6:00 PM18:00

London Session 2: Developing strategies for public engagement

The Science Innovation Union is offering a groundbreaking bio-entrepreneurship course aimed directly at the UK’s top scientists and budding entrepreneurs. The programme consists of a series of four exciting sessions lead by high profile leading academics and industry experts. Head to our website to sign up now! http://science-union.org/siu360-application

Links to other three session in the SIU360 series:
Session 1: https://www.facebook.com/events/1632034013488876/
Session 3: https://www.facebook.com/events/1653754461601574/
Session 4: https://www.facebook.com/events/104791129993224/

Session 2: Developing strategies for public engagement.
Sharing great science with an audience can be a difficult task when raised in the lab environment and trained to publish in scientific journals. Where can scientific outreach be taken? What is the best way to convey research to a non-scientific audience? How is a public outreach event planned and organised? What language needs to be used for the proposed science to be understood by a wide audience and how can the importance of this science be made clear? In this session speakers will demonstrate strategic plans for creating public outreach events. Attendees will learn how to build an image of their work that will be clear and engaging for a wide audience. 

Speaker: Steven Zimmer, BSc(Hon), MSc.-Founder, Director and CEO - MitoDys Therapeutics

Steven trained as a Biochemist and Molecular Biologist, Steven has had a long career as an analyst, investment banker and portfolio manager on Wall Street and in the City of London. He was a co-founder, Protein Sciences Inc., Steribottle Ltd and Tissuomics and has been an investor and advisor to many ventures and companies over the past 30 years. His latest position was as an advisor on Business and Strategic Development at e-Therapeutics plc, an AIM-listed network pharmacology-based drug discovery company based in Newcastle, UK.

View Event →
London Session 1: Platforms for translating research
Oct
27
6:00 PM18:00

London Session 1: Platforms for translating research

The Science Innovation Union is offering a groundbreaking bio-entrepreneurship course aimed directly at the UK’s top scientists and budding entrepreneurs. The programme consists of a series of four exciting sessions lead by high profile leading academics and industry experts. Head to our website to sign up now! http://science-union.org/siu360-application

Links to other three session in the SIU360 series:
Session 2: https://www.facebook.com/events/549654898557804/
Session 3: https://www.facebook.com/events/1653754461601574/
Session 4: https://www.facebook.com/events/104791129993224/

Session 1: Platforms for translating research.
For many scientists, translating research means publishing their work in a journal. These publications are critical in advancing our knowledge, however, a non-scientist audience would find it difficult to interpret these findings, and may therefore be excluded from the advancements scientist are achieving, which may be directly linked to the benefit of the public! In this session, the focus will be held on finding appropriate platforms for getting research known to the public. What organised events exist for bringing ideas forward? How to portray research so that it makes sense to a non-scientist? What are the best ways for exposing science to gain the largest impact? 

Speaker: Dr Amir Gander is the lead individual for Tissue Access for Patient Benefit (TAPb), a UCL initiative to bring surplus human tissue from surgery and biobanks to researchers across UK and internationally. Amir was involved with quality management and regulations and also specialised in the development of bench scale drug fermentation techniques to large production scales at a leading pharmaceutical production plant. TAPb has established a network of researchers interested in tissue from specific disease pathways. In collaboration with the state-of-the-art biobank at the Royal Free Hospital London, they have started to supply tissue (with clinical information) to a number of research companies and have strong ties with public and private sector researchers.

View Event →